LBA9 Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005)

Abstract

PD-L1 inhibitors have been approved for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy (chemo), marking a milestone in the management of this disease. Whether a PD-1 inhibitor provides similar or better benefits in the same patient population remains unclear. At 2022 ASCO Annual Meeting, we presented the results from the interim analysis of a phase 3 study of serplulimab, a novel anti-PD-1 antibody, in combination with chemo in previously untreated ES-SCLC patients.